Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma
Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma
复制标题
DOI：
10.1097/jto.0b013e31821e1c08
复制
发表时间：
2011-09-01
影响因子：
20.4
通讯作者：
Foddis, Rudy
中科院分区：
文献类型：
--
作者：
Cristaudo, Alfonso;Bonotti, Alessandra;Foddis, Rudy
简介：恶性胸膜间皮瘤（MPM）是一种与石棉暴露相关的致命肿瘤。目前，唯一的筛查和诊断工具是基于放射学测试，造成了明显的经济和放射保护主义问题。一些作者正在评估生物指标，例如血浆骨桥蛋白（pOPN）和血清可溶性间皮素相关肽（SMRP）。本研究旨在评估这两种标志物的组合是否可以提高上皮样 MPM 诊断的敏感性和特异性。方法：我们招募了 93 名健康受试者、111 名良性呼吸道疾病 (BRD) 患者和 31 名经组织学和/或细胞学证实的 MPM 患者。 SMRP 和 pOPN 水平使用市售酶联免疫吸附测定试剂盒测定。通过logistic回归分析，将SMRP和pOPN合并并转化为一个新的指数，称为“组合风险指数”。结果：上皮性MPM患者与健康受试者或BRD患者之间的SMRP和pOPN平均值差异有统计学意义（p <0.0001），而健康受试者和BRD患者之间SMRP和pOPN平均值没有差异。两种标记物的组合提高了 MPM 诊断的性能。我们的研究结果应该得到更大规模、可能的多中心研究的证实，这样可以更好地考虑一些可能的混杂因素，如肾小球滤过率和其他血液参数的影响。结论：我们结合SMRP和pOPN剂量以提高诊断准确性。这项研究首次表明，结合 SMRP 和 pOPN 测量可以提高组合风险指数的敏感性和特异性。
Introduction: Malignant pleural mesothelioma (MPM) is a lethal tumor related to asbestos exposure. At present, the only instruments for screening and diagnosis are based on radiological tests, posing evident economic and radio-protectionist problems. Some authors are evaluating biological indicators, such as plasma osteopontin (pOPN) and serum soluble mesothelin-related peptides (SMRP). This study aimed to evaluate whether a combination of these two markers could increase sensitivity and specificity in diagnosis of epithelioid MPM.Methods: We enrolled 93 healthy subjects, 111 individuals with benign respiratory disease (BRD), and 31 patients with MPM, histologically and/or cytologically confirmed. SMRP and pOPN levels were determined using commercially available enzyme-linked immunosorbent assay kits. Though a logistic regression analysis, SMRP and pOPN were combined and translated into a new index, called "combined risk index."Results: Differences in both SMRP and pOPN mean values between epithelial MPM patients and healthy subjects or BRD patients were statistically significant (p < 0.0001), whereas there was no difference in SMRP and pOPN mean values between healthy subjects and BRD patients. The performance in MPM diagnosis resulted improved by the combination of the two markers. The results of our study should be confirmed by a larger scale and, possibly, a multi-center study, which could better take into consideration the influence of some possible confounding factors such as glomerular filtration rate and other blood parameters.Conclusions: We combined SMRP and pOPN dosages to increase diagnostic accuracy. This study showed for the first time that combined SMRP and pOPN measurements can increase both sensitivity and specificity in terms of combined risk index.